Tepotinib: A Selective MET Inhibitor Revolutionizing the Treatment Landscape of Non-Small Cell Lung Cancer

Abstract

Introduction

Conventional therapies do not address the high death rate associated with non-small cell lung cancer or the side effects of chemotherapy. Tepotinib is a highly selective MET inhibitor that has demonstrated promising positive outcomes in treating patients with MET exon 14 skipping mutations, and it is one of the targeted therapeutic approaches. Preclinical and clinical studies on tepotinib's involvement in non-small cell lung cancer are reviewed in this article.

Methods

This article analyses the research and reviews from PubMed, Google Scholar, and Clinical Government sites for these keywords. I explored 150+ articles out of which 100 articles were used.

Results

In Phase II trials of NSCLC patients with MET exon 14 skipping mutations, tepotinib exhibited encouraging clinical activity. Peripheral edema, hypoalbuminemia, and pleural effusion were the common side effects. The drug's efficacy was further supported by its performance in combination with other targeted therapies, such as gefitinib and osimertinib.

Conclusion

Tepotinib shows significant advancement in the treatment of non-small cell lung cancer, especially for patients with MET exon 14 skipping mutation. The survival of tumor cells is hampered by the selective metabolic suppression of MET phosphorylation, which also suppresses oncogenic signaling. Future research endeavors will focus on exploring combination therapies, broadening the scope of indications in diverse solid tumors and carcinomas deduced from predictive biomarker analysis, and examining resistance mechanisms or patient responses. These findings demonstrate the potential benefits of tepotinib as a precision therapy for non-small cell lung cancer, an illness that is challenging to treat.